Comprehensive Stock Comparison
Compare Seres Therapeutics, Inc. (MCRB) vs Synlogic, Inc. (SYBX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  MCRB | 448.4% revenue growth vs SYBX's -99.8% |
| Quality / Margins | MCRB | 15.4% net margin vs SYBX's -2.9K% |
| Stability / Safety |  SYBX | Beta 0.97 vs MCRB's 1.21 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | MCRB | -40.3% vs SYBX's -53.1% |
| Efficiency (ROA) | MCRB | 3.8% ROA vs SYBX's -19.5%, ROIC -180.9% vs -205.7% |
Who Each Stock Is For
Income & stability
SYBXbeta 0.97
Growth exposure
MCRBRev growth 448.4%, EPS growth -6.2%
Long-term compounding (10Y)
SYBX-98.0% 10Y total return vs MCRB's -98.5%
Sleep-well-at-night portfolio
SYBXLower volatility, beta 0.97, current ratio 2.80x
Defensive / Recession hedge
SYBXBeta 0.97, current ratio 2.80x
Business Model
What each company does and how it makes money
Seres Therapeutics is a microbiome therapeutics company developing bacterial consortia treatments for serious diseases. It generates revenue primarily through collaboration agreements and milestone payments — notably with Nestlé Health Science — while advancing its lead candidate SER-109 toward FDA approval for recurrent C. difficile infection. The company's key advantage is its proprietary platform for rationally designing bacterial consortia that functionally interact with human biology, creating a technical moat in the emerging microbiome therapeutics field.
Synlogic is a clinical-stage biopharmaceutical company developing synthetic biotic medicines — engineered probiotics — to treat metabolic and immunological diseases. It generates revenue primarily through research collaborations and milestone payments from partners like Roche, with potential future income from drug sales if its pipeline succeeds. The company's key advantage lies in its proprietary platform for engineering bacterial strains to perform therapeutic functions in the gut — a novel approach distinct from traditional small molecules or biologics.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
MCRB 3SYBX 1MCRB3/4 metricsMCRB4/6 metricsMCRB5/6 metricsSYBX2/2 metricsMCRB leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). SYBX leads in 1 (Risk & Volatility). 1 tied.
Financial Metrics (TTM)
MCRB and SYBX operate at a comparable scale, with $351,000 and $0 in trailing revenue. MCRB is the more profitable business, keeping 15.4% of every revenue dollar as net income compared to SYBX's -2919.9%.
| Metric | MCRBSeres Therapeutic… | SYBXSynlogic, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $351,000 | $0 |
| EBITDAEarnings before interest/tax | -$99M | -$3M |
| Net IncomeAfter-tax profit | $5M | -$3M |
| Free Cash FlowCash after capex | -$23M | -$4M |
| Gross MarginGross profit ÷ Revenue | -50.1% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -294.7% | -5118.8% |
| Net MarginNet income ÷ Revenue | +15.4% | -2919.9% |
| FCF MarginFCF ÷ Revenue | -66.6% | -3959.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +112.3% | — |
Valuation Metrics
| Metric | MCRBSeres Therapeutic… | SYBXSynlogic, Inc. |
|---|---|---|
| Market CapShares × price | $80M | $7M |
| Enterprise ValueMkt cap + debt − cash | $141M | -$12M |
| Trailing P/EPrice ÷ TTM EPS | -0.48x | -0.31x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 877.42x |
| Price / BookPrice ÷ Book value/share | 5.15x | 0.57x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
MCRB delivers a 12.3% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-31 for SYBX.
| Metric | MCRBSeres Therapeutic… | SYBXSynlogic, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +12.3% | -31.3% |
| ROA (TTM)Return on assets | +3.8% | -19.5% |
| ROICReturn on invested capital | -180.9% | -2.1% |
| ROCEReturn on capital employed | -67.7% | -120.6% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 6.65x | — |
| Net DebtTotal debt minus cash | $61M | -$19M |
| Cash & Equiv.Liquid assets | $31M | $19M |
| Total DebtShort + long-term debt | $92M | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in MCRB five years ago would be worth $240 today (with dividends reinvested), compared to $117 for SYBX. Over the past 12 months, MCRB leads with a -40.3% total return vs SYBX's -53.1%. The 3-year compound annual growth rate (CAGR) favors MCRB at -56.4% vs SYBX's -60.9% — a key indicator of consistent wealth creation.
| Metric | MCRBSeres Therapeutic… | SYBXSynlogic, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -39.7% | -48.7% |
| 1-Year ReturnPast 12 months | -40.3% | -53.1% |
| 3-Year ReturnCumulative with dividends | -91.7% | -94.0% |
| 5-Year ReturnCumulative with dividends | -97.6% | -98.8% |
| 10-Year ReturnCumulative with dividends | -98.5% | -98.0% |
| CAGR (3Y)Annualised 3-year return | -56.4% | -60.9% |
Risk & Volatility
SYBX is the less volatile stock with a 0.97 beta — it tends to amplify market swings less than MCRB's 1.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | MCRBSeres Therapeutic… | SYBXSynlogic, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.21x | 0.97x |
| 52-Week HighHighest price in past year | $29.98 | $1.96 |
| 52-Week LowLowest price in past year | $6.53 | $0.54 |
| % of 52W HighCurrent price vs 52-week peak | +30.5% | +30.6% |
| RSI (14)Momentum oscillator 0–100 | 32.0 | 34.3 |
| Avg Volume (50D)Average daily shares traded | 69K | 113K |
Analyst Outlook
| Metric | MCRBSeres Therapeutic… | SYBXSynlogic, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $1.25 | — |
| # AnalystsCovering analysts | 18 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Seres Therapeutics,… (MCRB) | 100 | 12.66 | -87.3% |
| Synlogic, Inc. (SYBX) | 100 | 2.01 | -98.0% |
Seres Therapeutics,… (MCRB) returned -98% over 5 years vs Synlogic, Inc. (SYBX)'s -99%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Seres Therapeutics,… (MCRB) | $0.00 | $0.00 | — |
| Synlogic, Inc. (SYBX) | $0.00 | $8000.00 | — |
Seres Therapeutics, Inc.'s revenue grew from $0M (2015) to $0M (2024) — a 0.0% CAGR. Synlogic, Inc.'s revenue grew from $0M (2015) to $0M (2024) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2024 | Change |
|---|---|---|---|
| Seres Therapeutics,… (MCRB) | -4.2% | -45.2% | -975.5% |
| Synlogic, Inc. (SYBX) | -59.2% | -2919.9% | -4835.4% |
Synlogic, Inc.'s net margin went from -59% (2016) to -2920% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Seres Therapeutics,… (MCRB) | -46.6 | -18.86 | +59.5% |
| Synlogic, Inc. (SYBX) | -34.9 | -1.92 | +94.5% |
Seres Therapeutics, Inc.'s EPS grew from $-46.60 (2015) to $-18.86 (2024). Synlogic, Inc.'s EPS grew from $-34.90 (2015) to $-1.92 (2024).
Chart 5Free Cash Flow — 5 Years
Seres Therapeutics, Inc. generated $-149M FCF in 2024 (-5077% vs 2021). Synlogic, Inc. generated $-32M FCF in 2024 (+40% vs 2021).
MCRB vs SYBX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is MCRB or SYBX a better buy right now?
Analysts rate Seres Therapeutics, Inc. (MCRB) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MCRB or SYBX?
Over the past 5 years, Seres Therapeutics, Inc. (MCRB) delivered a total return of -97.6%, compared to -98.8% for Synlogic, Inc. (SYBX). A $10,000 investment in MCRB five years ago would be worth approximately $240 today (assuming dividends reinvested). Over 10 years, the gap is even starker: SYBX returned -98.0% versus MCRB's -98.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MCRB or SYBX?
By beta (market sensitivity over 5 years), Synlogic, Inc. (SYBX) is the lower-risk stock at 0.97β versus Seres Therapeutics, Inc.'s 1.21β — meaning MCRB is approximately 25% more volatile than SYBX relative to the S&P 500.
04Which has better profit margins — MCRB or SYBX?
Seres Therapeutics, Inc. (MCRB) is the more profitable company, earning 1537% net margin versus -2919.9% for Synlogic, Inc. — meaning it keeps 1537% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCRB leads at -294.7% versus -5118.8% for SYBX. At the gross margin level — before operating expenses — SYBX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — MCRB or SYBX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is MCRB or SYBX better for a retirement portfolio?
For long-horizon retirement investors, Synlogic, Inc. (SYBX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.97)). Both have compounded well over 10 years (SYBX: -98.0%, MCRB: -98.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between MCRB and SYBX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.